Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Taking the Plunge.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • المصدر:
    Pharmaceutical Executive. Jun2007, Vol. 27 Issue 6, p38-40. 2p.
  • معلومة اضافية
    • الموضوع:
      CELL Genesys Inc.; SHERWIN, Stephen; GENE therapy; IMMUNOTHERAPY; CANCER treatment
    • الموضوع:
      UNITED States
    • نبذة مختصرة :
      The article reports that chairman and chief executive officer Stephen Sherwin of Cell Genesys Inc. believes that the company could be the most promising gene activation, immunotheraphy and oncolytic virus therapy center in the U.S. According to the article, the company is developing GVAX, an immunotherapy vaccine for prostate, leukemia and pancreatic cancer. It is also developing a bladder-cancer drug based on a modified adenovirus that attacks tumor cells. INSET: A+ Is for Abgenix.